Helping achieve access:


  • Click here for detailed information about Medicare coverage (certain coverage limitations apply)
  • Reimbursed by many private insurance plans
  • Our Patient Services Team is available to assist your patients in the navigation of their experience with Biotheranostics. We will maintain contact with the patient to help educate and update throughout the process. Assists with:
    • Understanding of BCI billing policies
    • Applicability and enrollment into appropriate financial assistance programs
  • We offer a patient assistance program which alleviates the economic burden for many patients

Biotheranostics' Patient Services Team
Phone: 1-844-319-8111
Hours: M-F from 7AM-4PM (PST)

ICD-10 Code Reference

For Breast Caner Index, below is a list of covered diagnosis codes from the Medicare MoIDX Local Coverage Determination policy. These codes are provided as a guide to help you determine if the test is covered by Medicare based on medical necessity.

ICD-10 Code:
Right Breast
ICD-10 Code:
Left Breast
Description:
C50.011 C50.012 Malignant neoplasm of nipple and areola of female breast
C50.111 C50.112 Malignant neoplasm of central portion of female breast
C50.211 C50.212 Malignant neoplasm of upper-inner quadrant of female breast
C50.311 C50.312 Malignant neoplasm of lower-inner quadrant of female breast
C50.411 C50.412 Malignant neoplasm of upper-outer quadrant of female breast
C50.511 C50.512 Malignant neoplasm of lower-outer quadrant of female breast
C50.611 C50.612 Malignant neoplasm of auxillary tail of female breast
C50.811 C50.812 Malignant neoplasm of overlapping sites of female breast
C50.911 C50.912 Malignant neoplasm of breast (female) unspecified site
Z17.0 Z17.0 Estrogen receptor positive status (ER+)
References
  1. Gustavesen G, et al. Am J Manag Care. 2014;20:e302-e310.
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.

Biotheranostics Page

Biotheranostics, Inc. | 9640 Towne Centre Drive | Suite 200 | San Diego, CA 92121 | Biotheranostics.com

US and International: +1 (858) 587-5870 | Fax: +1 (800) 266-9607 | Client Services: +1 (877) 886-6739 | Billing Information: +1 (888) 286-0755 | Patient Advocates Team: +1 (844) 319-8111

© 2018 Biotheranostics, Inc. Breast Cancer Index and BCI are service marks of Biotheranostics, Inc.